Ozempic Launches in India
The weight loss medication Ozempic was released in India on Friday. The 0.25mg doses are priced at $24.35 per week.
Pharmaceutical company Novo Nordisk initiated this action as demand for weight loss therapies increases globally. The company stated that Ozempic will be available in injectable pens, with dosages of 0.25mg, 0.5mg, and 1mg. Health tracking apps like Shotlee can help monitor progress for individuals using such medications.
Pricing Details
Monthly costs in India have been established at 8,800 rupees ($97) for a 0.25mg dose. The 0.5mg dose will cost 10,170 rupees, while the 1mg dose is priced at 11,175 rupees per month. Each pen provides four weekly doses.
Ozempic's Popularity and Benefits
Ozempic, which gained approval from the US Food and Drug Administration in 2017 for treating Type 2 diabetes, has become increasingly popular. Its widespread use for weight loss is attributed to its appetite-suppressing qualities. Novo also noted its beneficial effects for individuals with cardiovascular and kidney problems.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
According to Vikrant Shrotriya, corporate vice president and managing director of Novo Nordisk India, "Ozempic also supports weight loss of up to 8kg in diabetic patients... therefore, this drug offers advantages beyond just controlling blood sugar levels."
Market Context
India has the second-largest population of individuals with Type 2 diabetes, following China. It also experiences rising obesity rates. This makes the country a crucial area for pharmaceutical firms competing for a portion of the rapidly expanding weight loss treatment market. Analysts project the sector will reach a valuation of $150 billion annually by the decade's end.
Novo launched Ozempic in India this month to establish a market presence before local companies introduce cheaper alternatives. Patents for semaglutide, the medication sold under the Ozempic and Wegovy brands, are set to expire in March 2026.
